Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 4
2004 5
2005 5
2006 3
2007 10
2008 7
2009 12
2010 6
2011 3
2012 4
2013 10
2014 5
2015 5
2016 2
2017 9
2018 11
2019 2
2020 6
2021 3
2022 8
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.
Pataskar A, Champagne J, Nagel R, Kenski J, Laos M, Michaux J, Pak HS, Bleijerveld OB, Mordente K, Navarro JM, Blommaert N, Nielsen MM, Lovecchio D, Stone E, Georgiou G, de Gooijer MC, van Tellingen O, Altelaar M, Joosten RP, Perrakis A, Olweus J, Bassani-Sternberg M, Peeper DS, Agami R. Pataskar A, et al. Among authors: van tellingen o. Nature. 2022 Mar;603(7902):721-727. doi: 10.1038/s41586-022-04499-2. Epub 2022 Mar 9. Nature. 2022. PMID: 35264796 Free PMC article.
Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.
Mertens S, Huismans MA, Verissimo CS, Ponsioen B, Overmeer R, Proost N, van Tellingen O, van de Ven M, Begthel H, Boj SF, Clevers H, Roodhart JML, Bos JL, Snippert HJG. Mertens S, et al. Among authors: van tellingen o. Cell Rep. 2023 Apr 25;42(4):112324. doi: 10.1016/j.celrep.2023.112324. Epub 2023 Mar 30. Cell Rep. 2023. PMID: 37000626 Free article.
An Experimenter's Guide to Glioblastoma Invasion Pathways.
de Gooijer MC, Guillén Navarro M, Bernards R, Wurdinger T, van Tellingen O. de Gooijer MC, et al. Among authors: van tellingen o. Trends Mol Med. 2018 Sep;24(9):763-780. doi: 10.1016/j.molmed.2018.07.003. Epub 2018 Jul 30. Trends Mol Med. 2018. PMID: 30072121 Review.
BCRP drives intrinsic chemoresistance in chemotherapy-naïve breast cancer brain metastasis.
Uceda-Castro R, Margarido AS, Song JY, de Gooijer MC, Messal HA, Chambers CR, Nobis M, Çitirikkaya CH, Hahn K, Seinstra D, Herrmann D, Timpson P, Wesseling P, van Tellingen O, Vennin C, van Rheenen J. Uceda-Castro R, et al. Among authors: van tellingen o. Sci Adv. 2023 Oct 20;9(42):eabp9530. doi: 10.1126/sciadv.abp9530. Epub 2023 Oct 18. Sci Adv. 2023. PMID: 37851804 Free PMC article.
Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis.
Uceda-Castro R, Margarido AS, Cornet L, Vegna S, Hahn K, Song JY, Putavet DA, van Geldorp M, Çitirikkaya CH, de Keizer PLJ, Ter Beek LC, Borst GR, Akkari L, van Tellingen O, Broekman MLD, Vennin C, van Rheenen J. Uceda-Castro R, et al. Among authors: van tellingen o. Cell Rep Med. 2022 Nov 15;3(11):100821. doi: 10.1016/j.xcrm.2022.100821. Cell Rep Med. 2022. PMID: 36384097 Free PMC article.
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.
Frank KJ, Mulero-Sánchez A, Berninger A, Ruiz-Cañas L, Bosma A, Görgülü K, Wu N, Diakopoulos KN, Kaya-Aksoy E, Ruess DA, Kabacaoğlu D, Schmidt F, Kohlmann L, van Tellingen O, Thijssen B, van de Ven M, Proost N, Kossatz S, Weber WA, Sainz B Jr, Bernards R, Algül H, Lesina M, Mainardi S. Frank KJ, et al. Among authors: van tellingen o. Cell Rep Med. 2022 Nov 15;3(11):100815. doi: 10.1016/j.xcrm.2022.100815. Cell Rep Med. 2022. PMID: 36384095 Free PMC article.
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Mulero-Sánchez A, Ramirez CFA, du Chatinier A, Wang H, Koomen SJI, Song JY, de Groot MHP, Lieftink C, Bosma A, Burylo A, van Tellingen O, Beijersbergen RL, Wang C, Akkari L, Bernards R, Mainardi S. Mulero-Sánchez A, et al. Among authors: van tellingen o. Mol Oncol. 2023 Jun;17(6):964-980. doi: 10.1002/1878-0261.13377. Epub 2023 Feb 9. Mol Oncol. 2023. PMID: 36650715 Free PMC article.
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.
Chen M, Mainardi S, Lieftink C, Velds A, de Rink I, Yang C, Kuiken HJ, Morris B, Edwards F, Jochems F, van Tellingen O, Boeije M, Proost N, Jansen RA, Qin S, Jin H, Koen van der Mijn JC, Schepers A, Venkatesan S, Qin W, Beijersbergen RL, Wang L, Bernards R. Chen M, et al. Among authors: van tellingen o. Cell Rep Med. 2024 Mar 19;5(3):101471. doi: 10.1016/j.xcrm.2024.101471. Cell Rep Med. 2024. PMID: 38508142 Free PMC article.
Buparlisib is a brain penetrable pan-PI3K inhibitor.
de Gooijer MC, Zhang P, Buil LCM, Çitirikkaya CH, Thota N, Beijnen JH, van Tellingen O. de Gooijer MC, et al. Among authors: van tellingen o. Sci Rep. 2018 Jul 17;8(1):10784. doi: 10.1038/s41598-018-29062-w. Sci Rep. 2018. PMID: 30018387 Free PMC article.
116 results